Boehringer and Gubra collaborate to discover peptide compounds for obesity treatment

Germany-based Boehringer Ingelheim has entered a collaboration and licensing agreement with Danish biotech company Gubra to develop new peptide compounds to treat obesity.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news